FDA Questions Innovation Gap, Says Me-Too Drugs Drive Approval Fluctuations
This article was originally published in The Pink Sheet Daily
Executive Summary
Using first-in-class status as a sign of innovation, an FDA analysis finds approval numbers have been fairly stable during the past 25 years; the variability comes from follow-on products.